このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Illumina マネジメント

マネジメント基準チェック /34

Illumina'sの CEO はJacob Thaysenで、 Sep2023年に任命され、の在任期間は 1.08年です。の年間総報酬は$ 4.69Mで、 5.3%給与と94.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.005%を直接所有しており、その価値は€ 862.16K 。経営陣と取締役会の平均在任期間はそれぞれ2年と6.3年です。

主要情報

Jacob Thaysen

最高経営責任者

US$4.7m

報酬総額

CEO給与比率	5.3%
CEO在任期間	1.1yrs
CEOの所有権	0.005%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Illumina の収益と比較して、Jacob Thaysen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$5m	US$250k	-US$1b

報酬と市場: Jacobの総報酬 ($USD 4.69M ) は、 German市場 ($USD 5.00M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jacobの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Jacob Thaysen (49 yo)

1.1yrs

在職期間

US$4,691,233

報酬

Mr. Jacob Thaysen, Ph.D. serves as Chief Executive Officer at Illumina, Inc. since September 25, 2023 and serves as its Director since September 2023. Mr. Thaysen joined the Illumina, Inc. in September 202...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jacob Thaysen	CEO & Director	1.1yrs	US$4.69m	0.0046% $ 910.4k
Carissa Rollins	Chief Information Officer	2.6yrs	US$2.93m	0.0011% $ 211.8k
Charles Dadswell	Senior VP & General Counsel	11.5yrs	US$4.10m	0.0044% $ 876.7k
Stephanie Campos	President	no data	データなし	データなし
Ankur Dhingra	Chief Financial Officer	no data	データなし	データなし
Kevin Pegels	Chief of Global Operations	2.9yrs	データなし	0.011% $ 2.1m
Scott Ericksen	VP & Chief Accounting Officer	2yrs	データなし	0.0067% $ 1.3m
Steven Barnard	Chief Technology Officer	1.2yrs	データなし	0.017% $ 3.4m
Sallilyn Schwartz	Vice President of Investor Relations	3.8yrs	データなし	データなし
Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	less than a year	データなし	0.0044% $ 870.8k
Pat Leckman	Senior VP & Chief People Officer	less than a year	データなし	0.0055% $ 1.1m
Nicole Berry	Head of Region-Americas	no data	データなし	データなし

2.0yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: ILUの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jacob Thaysen	CEO & Director	1.1yrs	US$4.69m	0.0046% $ 910.4k
Caroline Dorsa	Independent Director	7.8yrs	US$408.88k	0.0062% $ 1.2m
Susan Siegel	Independent Director	5.7yrs	US$398.58k	0.0050% $ 995.5k
Stephen MacMillan	Independent Chairman of the Board	1.3yrs	US$388.22k	0.00095% $ 188.0k
Philip Schiller	Independent Director	8.3yrs	US$395.10k	0.0086% $ 1.7m
Robert Epstein	Independent Director	11.9yrs	US$405.10k	0.0098% $ 1.9m
Gary Guthart	Independent Director	6.8yrs	US$404.29k	0.0063% $ 1.2m
Scott Ullem	Independent Director	1.3yrs	US$345.03k	0.0013% $ 255.3k
Frances Arnold	Independent Director	8.8yrs	US$400.10k	0.0092% $ 1.8m
Leslie Biesecker	Member of Ethics Advisory Board	no data	データなし	データなし
Scott Gottlieb	Independent Director	4.7yrs	US$391.37k	0.0035% $ 692.7k
Clement Adebamowo	Member of Ethics Advisory Board	no data	データなし	データなし

6.3yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: ILUの取締役会は経験豊富であると考えられます ( 5.9年の平均在任期間)。

Illumina マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Illumina, Inc. Announces Executive Changes

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Announces CEO Changes

Recent updates

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Second quarter 2024 earnings released: US$12.50 loss per share (vs US$1.48 loss in 2Q 2023)

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Now 21% undervalued

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Illumina, Inc. Appoints Anna Richo to its Board of Directors

First quarter 2024 earnings released: US$0.79 loss per share (vs US$0.019 profit in 1Q 2023)

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 24% undervalued after recent price drop

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: US$7.35 loss per share (vs US$28.05 loss in FY 2022)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 21% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

New minor risk - Share price stability

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Third quarter 2023 earnings released: US$4.77 loss per share (vs US$24.31 loss in 3Q 2022)

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.48 loss per share (vs US$3.41 loss in 2Q 2022)

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Illumina, Inc. Announces CEO Changes

Illumina, Inc. Announces Board Changes

Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients

Chief Commercial Officer recently sold €966k worth of stock

Illumina, Inc. Announces Board Changes

First quarter 2023 earnings released: EPS: US$0.019 (vs US$0.55 in 1Q 2022)

Full year 2022 earnings released: US$28.05 loss per share (vs US$5.08 profit in FY 2021)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Appoints Joydeep Goswami as Chief Financial Officer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$24.31 loss per share (vs US$2.09 profit in 3Q 2021)

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022

Illumina Intends to Appeal EC's Decision in Grail Deal

Second quarter 2022 earnings released: US$3.41 loss per share (vs US$1.27 profit in 2Q 2021)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

Illumina, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Illumina, Inc.(NasdaqGS:ILMN) dropped from Russell 1000 Growth-Defensive Index

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Investor sentiment deteriorated over the past week

マネジメント基準チェック /34